Annual Report for the financial year 2024-2025.
ABBOTINDIA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Abbott India has submitted its Annual Report for FY 2024-25 along with the notice for its 81st Annual General Meeting, scheduled for August 13, 2025 at 10:00 AM via video conferencing. The company reported total revenue of Rs. 6,409 crore, up 9.6% year-on-year, with profit after tax rising 17.8% to Rs. 1,414 crore and EBITDA growing 15.8% to Rs. 1,970 crore. The Board has recommended a final dividend of Rs. 475 per share, payable on or after August 18, 2025 to shareholders on record as of July 25, 2025. During the year, Abbott India launched 7 new products, with 8 brands ranked in the Top 100 of the Indian Pharmaceutical Market and 16 brands holding #1 or #2 positions in their respective markets. Leadership transitioned with Swati Dalal stepping down as Managing Director on June 13, 2025, and Kartik Rajendran taking over on June 14, 2025.
Strong financial performance with double-digit profit growth and a healthy 15.9% increase in dividend is positive for shareholders, though the stock may already reflect these results. Leadership change at the top is a key watchpoint for execution continuity.